Cargando…
TGN1412: From Discovery to Disaster
After a drug is confirmed as safe and efficacious in preclinical studies, it is tested in healthy human volunteers for first in man trials. In 2006, a phase I clinical study was conducted for a CD28 superagonist antibody TGN1412 in six human volunteers. After very first infusion of a dose 500 times...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964774/ https://www.ncbi.nlm.nih.gov/pubmed/21042496 http://dx.doi.org/10.4103/0975-1483.66810 |